Onconetix holds annual stockholder meeting
ONCO•Onconetix shareholders approved issuing up to 154,856,150 common shares upon conversion of Series F Preferred Stock and authorized the board to execute a 1-for-2 to 1-for-15 reverse split within one year.
1. Shareholder approvals
At its November 10, 2026 annual meeting, Onconetix shareholders approved issuing up to 154,856,150 common shares upon conversion of Series F Preferred Stock. They authorized the board to choose and execute a reverse split ratio from 1-for-2 to 1-for-15 within one year.
2. Other meeting results
Josh Epstein was elected as a Class II director, and shareholders ratified MaloneBailey as independent auditor for the fiscal year ending December 31, 2026. They also authorized adjournment to solicit additional proxies if needed to secure proposal approvals.
